Brooklyn ImmunoTherapeutics Inc. [AMEX: BTX] jumped around 2.98 points on Monday, while shares priced at $16.97 at the close of the session, up 21.30%. The company report on May 24, 2021 that Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing.
Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, announced it has completed a $20M financing to progress the development of the mRNA gene editing and cell therapies technology recently licensed from Factor Biosciences and Novellus Therapeutics.
The Company intends to utilize the funds to commence translation of the gene editing, cellular therapy and nanolipid particle platform into its emerging clinical programs with a focus on orphan diseases, such as sickle cell anemia, familial amyloidosis and cell therapies for cancer.
Compared to the average trading volume of 6.05M shares, BTX reached a trading volume of 25609978 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Brooklyn ImmunoTherapeutics Inc. [BTX]?
The Average True Range (ATR) for Brooklyn ImmunoTherapeutics Inc. is set at 8.03, with the Price to Sales ratio for BTX stock in the period of the last 12 months amounting to 144.04. The Price to Book ratio for the last quarter was 29.26, with the Price to Cash per share for the same quarter was set at 0.02.
How has BTX stock performed recently?
Brooklyn ImmunoTherapeutics Inc. [BTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.49. With this latest performance, BTX shares gained by 5.01% in over the last four-week period, additionally plugging by 351.33% over the last 6 months – not to mention a rise of 637.83% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BTX stock in for the last two-week period is set at 44.54, with the RSI for the last a single of trading hit 39.96, and the three-weeks RSI is set at 47.80 for Brooklyn ImmunoTherapeutics Inc. [BTX], while it was recorded at 16.86 for the last single week of trading.
Brooklyn ImmunoTherapeutics Inc. [BTX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Brooklyn ImmunoTherapeutics Inc. [BTX] shares currently have an operating margin of -93.09 and a Gross Margin at +46.41. Brooklyn ImmunoTherapeutics Inc.’s Net Margin is presently recorded at -76.12.
Return on Total Capital for BTX is now -76.52, given the latest momentum, and Return on Invested Capital for the company is -94.09. Return on Equity for this stock declined to -148.60, with Return on Assets sitting at -45.35. When it comes to the capital structure of this company, Brooklyn ImmunoTherapeutics Inc. [BTX] has a Total Debt to Total Equity ratio set at 245.59. Additionally, BTX Total Debt to Total Capital is recorded at 71.06, with Total Debt to Total Assets ending up at 49.83. Long-Term Debt to Equity for the company is recorded at 62.59, with the Long-Term Debt to Total Capital now at 18.09.
Reflecting on the efficiency of the workforce at the company, Brooklyn ImmunoTherapeutics Inc. [BTX] managed to generate an average of -$200,682 per employee. Receivables Turnover for the company is 8.85 with a Total Asset Turnover recorded at a value of 0.60.Brooklyn ImmunoTherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.70.
Insider trade positions for Brooklyn ImmunoTherapeutics Inc. [BTX]
There are presently around $3 million, or 0.40% of BTX stock, in the hands of institutional investors. The top three institutional holders of BTX stocks are: EAGLE ASSET MANAGEMENT INC with ownership of 46,826, which is approximately 33.172% of the company’s market cap and around 8.10% of the total institutional ownership; CITADEL ADVISORS LLC, holding 22,849 shares of the stock with an approximate value of $0.32 million in BTX stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $0.28 million in BTX stock with ownership of nearly New of the company’s market capitalization.
Positions in Brooklyn ImmunoTherapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 8 institutional holders increased their position in Brooklyn ImmunoTherapeutics Inc. [AMEX:BTX] by around 83,047 shares. Additionally, 5 investors decreased positions by around 8,214 shares, while 3 investors held positions by with 58,082 shares. The mentioned changes placed institutional holdings at 149,343 shares, according to the latest SEC report filing. BTX stock had 5 new institutional investments in for a total of 55,650 shares, while 2 institutional investors sold positions of 8,124 shares during the same period.